Compare Abbott Laboratories (ABT) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Enveric Biosciences Inc — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.84M). The key difference: Abbott Laboratories is far larger — about 28585.6× Enveric Biosciences Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ABT | ENVB | |
|---|---|---|
Market Cap | $166.94B | $5.84M |
Sector | Health | Health |
52-Week High | $136.62 | $17.40 |
52-Week Low | $82.57 | $1.28 |
Enterprise Value | $193.69B | $932.52K |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
